GBIM - Globeimmune Stock Price, News & Analysis

$0.58 0.03 (5.45 %)
(As of 11/24/2017 08:00 AM ET)
Previous Close$0.58
Today's Range$0.59 - $0.56
52-Week Range$0.11 - $0.90
Volume5,200 shs
Average Volume5,042 shs
Market Capitalization$3.34 million
P/E RatioN/A
Dividend YieldN/A

About Globeimmune (OTCMKTS:GBIM)

Globeimmune logoGlobeImmune, Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company's segment is the business of developing and commercializing various biopharmaceutical products. The Company's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.

Industry, Sector and Symbol

Industry Biotechnology
  • Previous Symbol: NASDAQ:GBIM


    Debt-to-Equity RatioN/A
    Current RatioN/A
    Quick RatioN/A


    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual Sales$6.46 million
    Price / Sales0.52
    Cash FlowN/A
    Price / CashN/A
    Book Value$0.52 per share
    Price / Book1.12


    Annual DividendN/A
    Dividend YieldN/A


    Trailing EPSN/A
    Net IncomeN/A
    Net MarginsN/A
    Return on EquityN/A
    Return on AssetsN/A


    Outstanding Shares5,750,000

    Frequently Asked Questions for Globeimmune (OTCMKTS:GBIM)

    What is Globeimmune's stock symbol?

    Globeimmune trades on the OTCMKTS under the ticker symbol "GBIM."

    How were Globeimmune's earnings last quarter?

    Globeimmune, Inc. (OTCMKTS:GBIM) released its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter. View Globeimmune's Earnings History.

    Who are some of Globeimmune's key competitors?

    Who are Globeimmune's key executives?

    Globeimmune's management team includes the folowing people:

    • J. William Freytag Ph.D., Independent Chairman of the Board
    • Timothy C. Rodell M.D., President, Chief Executive Officer, Director
    • C. Jeffrey Dekker CPA, Vice President - Finance, Treasurer, Secretary
    • Augustine J. Lawlor, Independent Director
    • Daniel J. Mitchell, Independent Director
    • S. Edward Torres, Independent Director

    How do I buy Globeimmune stock?

    Shares of Globeimmune can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is Globeimmune's stock price today?

    One share of Globeimmune stock can currently be purchased for approximately $0.58.

    How big of a company is Globeimmune?

    Globeimmune has a market capitalization of $3.34 million and generates $6.46 million in revenue each year.

    How can I contact Globeimmune?

    Globeimmune's mailing address is 1450 INFINITE DRIVE, LOUISVILLE CO, 80027. The biopharmaceutical company can be reached via phone at 303-625-2700 or via email at [email protected]

    MarketBeat Community Rating for Globeimmune (GBIM)

    Community Ranking:  2.2 out of 5 (star star)
    Outperform Votes:  25 (Vote Outperform)
    Underperform Votes:  32 (Vote Underperform)
    Total Votes:  57
    MarketBeat's community ratings are surveys of what our community members think about Globeimmune and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Globeimmune (OTCMKTS:GBIM)

      (How are Consensus Ratings Calculated?)
    Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
    Consensus Rating:N/A (Score: NaN)
    Analysts' Consensus Price Target: N/A

    Consensus Price Target History for Globeimmune (OTCMKTS:GBIM)

    Price Target History for Globeimmune (OTCMKTS:GBIM)

    Analysts' Ratings History for Globeimmune (OTCMKTS:GBIM)

    No equities research coverage for this company has been tracked by


    Earnings History and Estimates Chart for Globeimmune (OTCMKTS:GBIM)

    Earnings by Quarter for Globeimmune (OTCMKTS:GBIM)

    Earnings History by Quarter for Globeimmune (OTCMKTS GBIM)

    DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
    5/12/2016Q1($0.27)($0.15)$0.94 millionViewN/AView Earnings Details
    (Data available from 1/1/2011 forward)


    Earnings Estimates for Globeimmune (OTCMKTS:GBIM)

    No earnings estimates for this company have been tracked by


    Dividend History for Globeimmune (OTCMKTS:GBIM)
    No dividend announcements for this company have been tracked by

    Insider Trades

    Insider Trading and Institutional Ownership History for Globeimmune (OTCMKTS GBIM)

    Insider Ownership Percentage: 23.50%
    Insider Trades by Quarter for Globeimmune (OTCMKTS:GBIM)

    Insider Trades by Quarter for Globeimmune (OTCMKTS GBIM)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    3/18/2016Augustine LawlorDirectorSell11,000$1.55$17,050.00View SEC Filing  
    3/17/2016Daniel J MitchellDirectorSell21,600$1.66$35,856.00View SEC Filing  
    3/15/2016Daniel J MitchellDirectorSell130,269$2.26$294,407.94View SEC Filing  
    3/11/2016Augustine LawlorDirectorSell16,500$1.60$26,400.00View SEC Filing  
    3/10/2016Daniel J MitchellDirectorSell16,400$1.17$19,188.00View SEC Filing  
    3/8/2016Augustine LawlorDirectorSell15,010$1.05$15,760.50View SEC Filing  
    3/7/2016Daniel J MitchellDirectorSell11,920$1.05$12,516.00View SEC Filing  
    3/3/2016Augustine LawlorDirectorSell15,990$1.11$17,748.90View SEC Filing  
    3/2/2016Daniel J MitchellDirectorSell17,422$1.02$17,770.44View SEC Filing  
    3/1/2016Daniel J MitchellDirectorSell8,799$0.96$8,447.04View SEC Filing  
    2/29/2016Augustine LawlorDirectorSell15,000$0.98$14,700.00View SEC Filing  
    2/26/2016Daniel J MitchellDirectorSell12,501$1.03$12,876.03View SEC Filing  
    2/24/2016Augustine LawlorDirectorSell15,000$1.33$19,950.00View SEC Filing  
    2/23/2016Daniel J MitchellDirectorSell22,858$1.42$32,458.36View SEC Filing  
    2/22/2016Augustine LawlorDirectorSell5,000$1.43$7,150.00View SEC Filing  
    2/19/2016Ventures Vii Lp HealthcareInsiderSell15,000$1.44$21,600.00View SEC Filing  
    2/18/2016Daniel J MitchellDirectorSell21,897$1.45$31,750.65View SEC Filing  
    2/16/2016Ventures Vii Lp HealthcareMajor ShareholderSell15,000$1.61$24,150.00View SEC Filing  
    2/12/2016Daniel J MitchellDirectorSell3,645$1.75$6,378.75View SEC Filing  
    2/9/2016Daniel J MitchellDirectorSell7,300$2.05$14,965.00View SEC Filing  
    7/8/2014Celgene International IncMajor ShareholderBuy200,000$10.00$2,000,000.00View SEC Filing  
    7/8/2014S. Edward TorresDirectorBuy85,000$10.00$850,000.00View SEC Filing  
    7/8/2014Timothy C Rodell JrCEOBuy5,000$10.00$50,000.00View SEC Filing  
    (Data available from 1/1/2013 forward)


    Latest Headlines for Globeimmune (OTCMKTS GBIM)

    Globeimmune, Inc. (GBIM) Stock Rating Upgraded by ValuEngineGlobeimmune, Inc. (GBIM) Stock Rating Upgraded by ValuEngine - November 20 at 10:52 PM

    Social Media



    Globeimmune (OTCMKTS GBIM) Chart for Friday, November, 24, 2017
    Loading chart…

    This page was last updated on 11/24/2017 by Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.